Analyst Price Target is C$3.00
▲ +1,202.65% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Alpha Cognition in the last 3 months. The average price target is C$3.00, with a high forecast of C$3.00 and a low forecast of C$3.00. The average price target represents a 1,202.65% upside from the last price of C$0.23.
Current Consensus is
The current consensus among 1 polled investment analysts is to hold stock in Alpha Cognition.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.